The biotechnology firm, TC BioPharm (Holdings) plc (TCBP), unveiled plans to acquire a privately-owned biotech company. The targeted business focuses on cultivating innovative Chimeric Antigen Receptor T-cell (CAR-T) treatments aimed at addressing intractable cancers and solid tumors.
This marks the second such agreement in consecutive months, demonstrating TC BioPharm's commitment to its merger and acquisition strategy that intends to broaden its therapeutic platform.
CAR T-cell therapy presents a novel approach by modifying a patient's own immune cells to allow a heightened capacity for the detection and eradication of cancer cells.
The company earmarked for acquisition has pioneered several proprietary methods to enhance CARs to improve targeting of solid tumors. Pre-clinical proof of concept data exhibits the promising therapeutic potential of its flagship CAR-T candidate in addressing an array of solid tumors, including colorectal, pancreatic, ovarian, breast cancer, and mesothelioma.
Furthermore, the company is also in the process of developing a new, allogeneic CAR-T treatment for autoimmune diseases.
